About Dendreon
Dendreon is a biotechnology company focused on innovative cancer therapies. We are dedicated to the research and development of personalized treatments that empower patients with actionable options against cancer. Our flagship product, Provenge, is the first FDA-approved cancer immunotherapy for prostate cancer, and it has paved the way for further advancements in the field.
At Dendreon, we continue to invest in scientific research, clinical trials, and new treatment modalities to improve patient outcomes. Our team is passionate about pushing the boundaries of science to enhance the lives of individuals battling cancer. By leveraging cutting-edge technology and a commitment to innovation, we strive to redefine the future of cancer care.
FAQs
- When was Dendreon founded?
- Dendreon was founded in 1992.
- Who is the CEO of Dendreon?
- Mark D. Brouckman is the CEO.
- What industries or markets does Dendreon operate in?
- Dendreon operates in the following markets: Biotechnology, Cancer Treatment, Immunotherapy, Healthcare, Life Sciences, Oncology, Personalized Medicine, Medical Research, Clinical Trials, and Pharmaceutical.
- How many employees does Dendreon have?
- Dendreon has 201-500 employees.
- Where does Dendreon have employees?
- Dendreon has employees in United States.
- Is Dendreon hiring?
- Yes, Dendreon has 4 open remote jobs.
- Does Dendreon support remote work or working from home?
- Yes, Dendreon is a remote-friendly company.
- Does Dendreon offer a four-day work week?
- No, Dendreon does not offer a four-day work week.
- What is Dendreon's website?
- Dendreon's website is www.dendreon.com.
United States
